Histidyl-tRNA synthetase-Fc conjugates
The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
1. A method of reducing a lung inflammatory response in a subject in need thereof, comprising administering to the subject a composition comprising a histidyl-tRNA synthetase (HRS) fusion polypeptide having at least one Fc region (HRS-Fc fusion polypeptide), wherein the HRS-Fc fusion polypeptide has an amino acid sequence that is at least 95% identical to SEQ ID NO:337, wherein the HRS-Fc fusion polypeptide is at least about 95% pure and less than about 5% aggregated, and wherein the composition is substantially endotoxin-free.
2. The method of claim 1 , wherein the HRS-Fc fusion polypeptide reduces immune cell activation and invasion into damaged lung.
3. The method of claim 1 , wherein the HRS-Fc fusion polypeptide increases production of anti-inflammatory cytokines, reduces production or activity of pro-inflammatory cytokines, or both.
4. The method of claim 1 , wherein the HRS fusion polypeptide comprises an amino acid sequence at least 97% identical to SEQ ID NO: 337.
5. The method of claim 4 , wherein the HRS fusion polypeptide comprises an amino acid sequence at least 98% identical to SEQ ID NO: 337.
6. The method of claim 1 , wherein the Fc region and the HRS polypeptide are separated by a peptide linker.
7. The method of claim 1 , wherein the HRS-Fc fusion polypeptide is substantially in dimeric form in a physiological solution.
8. The method of claim 1 , wherein the HRS-Fc fusion polypeptide has substantially the same secondary structure as a corresponding unmodified HRS polypeptide, as determined via UV circular dichroism analysis.
9. The method of claim 1 , wherein the HRS-Fc fusion polypeptide has a plasma or sera pharmacokinetic AUC profile at least 5-fold greater than a corresponding, unmodified HRS polypeptide.
10. The method of claim 1 , comprising intravenously administering the composition to the subject.
11. The method of any one of claims 1 - 10 , wherein the subject has problems with breathing.
12. The method of claim 1 , wherein the problems with breathing comprise shortness of breath, a non-productive cough, or both.